GlassScriptPhysician profile
Sevak T Ohanian
NPI 1922180637
$18,688.25
in general payments reported to CMS, 2019-2025
71 companies · $3,427 in 2025
The $3,427 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,140 · 2020: $2,025 · 2021: $1,996 · 2022: $2,490 · 2023: $2,482 · 2024: $3,128 · 2025: $3,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,961 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,961.14 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,482.84 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,293.18 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $1,272.69 | 2020-2025 | |
| Boston Scientific Corporation | $938.06 | 2019-2025 | Vercise, General - Dbs, Bionic Navigator |
| Amneal Pharmaceuticals LLC | $840.27 | 2019-2025 | Rytary, Crexont, Ongentys |
| Abbott Laboratories | $752.12 | 2019-2025 | Infinity |
| Lilly USA, LLC | $749.22 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Pfizer INC. | $704.95 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $685.59 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $643.60 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $607.49 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $548.13 | 2019-2025 | |
| Ucb, INC. | $546.76 | 2019-2025 | Rystiggo |
| Lundbeck LLC | $502.49 | 2020-2025 | Vyepti, Rexulti |
| Allergan, INC. | $465.92 | 2019-2022 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevak Ohanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.